Abstract The recent isolation of the gene responsible for multiple endocrine neoplasia type 1 (MEN 1) has enabled direct genetic diagnosis for people with endocrine tumors and family members of affected patients. Although MEN 1 is rarely recognized in the Japanese population compared to its prevalence in Caucasians, we have previously reported a high prevalence of this disease in a limited area (Nagano Prefecture; population, 2.15 million). In this communication, we report mutations of the MEN1 gene in kindreds living in Nagano Prefecture. The absence of a common mutation among these kindreds indicates that the high prevalence of MEN 1 in this area is not due to a regional accumulation of patients descended from a common ancestor. This result implies that the prevalence of MEN 1 in other areas of Japan could also be higher than had been thought.
Introduction
Multiple endocrine neoplasia type 1 (MEN 1) is a syndrome characterized by a hyperplastic or neoplastic disorder of endocrine organs. The gene responsible for MEN 1, designated MEN1, has recently been identified by two independent groups ; The European Consortium on MEN1 1997). The MEN1 gene consists of one non-coding exon and nine coding exons that encode a 610-amino-acid protein, "menin". Germline mutations of the MEN1 gene have been identified in most people with familial and sporadic MEN 1 (Chardrasekharappa et al. 1997 ; The European Consortium on MEN1 1997; Agarwal et al. 1997; Bassett et al. 1998) . No apparent hot spots have been observed, suggesting that the entire coding region is important for the as yet unknown functions of the menin protein.
Although several MEN1 gene mutations have been reported in Japanese patients (Shimizu et al. 1997; Tanaka et al. 1998) , MEN 1 has rarely been recognized in Japan (Yoshimoto and Saito 1991) . We have previously reported that the prevalence of this syndrome in a limited area of Japan (Nagano Prefecture; population, 2.15 million) is not significantly different from that in Caucasians, and the apparently low prevalence of MEN 1 in other areas of Japan may be due to an incomplete recognition of this disease (Katai et al. 1997) . To exclude the possibility that Nagano prefecture is a geographic exception, as are Tasmania and Newfoundland (Shepherd, 1991; Petty et al. 1994) where patients originating from common ancestors reside in islands, we analyzed the MEN1 gene mutations in patients living in Nagano Prefecture. whose analysis is reported in this communication have lived in Nagano Prefecture for more than three generations. Blood samples were drawn from patients and family members, with their written informed consents, and highmolecular weight DNA was isolated, as described previously (Sakurai et al. 1996) . Oligonucleotide primers for amplification and sequencing of the MEN1 gene were prepared according to the information available at the web site, http://www.nhgri.nih.gov/DIR/LGT/MEN1/table 1.html . DNA fragments amplified by polymerase chain reaction (PCR) were purified and directly sequenced using the ABI PRISM310 Genetic Analyzer (Perkin-Elmer, Foster City, CA, USA) with appropriate sequencing primers. Mutations were confirmed either by sequencing both strands or by restriction digestion when suitable enzymes were available.
Results
Among 14 families studied for mutations in the MEN1 gene, we identified eight different germline mutations in 11 families. These are summarized in Table 1 . There were two in-frame deletions in three families, four frame-shift deletions in four families, and two frame-shift insertions in four families. In three families, no mutations were found in exons 2 to 10 and exon/intron boundaries. Three mutations, 359del4, K119del, and 1657insC were identical to those previously reported (Table 1) . When appropriate restriction sites were available, family members were screened for mutations by digestion of amplified DNA fragments. Cosegregation of the MEN1 gene mutations and disease phenotype was observed in all families examined. As has been reported (Bassett et al. 1998) , no apparent genotypephenotype correlation was observed among the patients.
Discussion
The absence of a common ancestral mutation among patients living in Nagano Prefecture indicates that the high prevalence of MEN 1 in this area is not due to a founder effect, and this may allow the prediction of a similar prevalence in other areas of Japan. As we have previously reasoned (Katai et al. 1997) , many patients may still be left unrecognized in Japan. The diagnosis of MEN 1 early in its clinical course is crucial for a better prognosis (Wilkinson et al. 1993) , and collection of clinical information on patients will enable better management of this disease.
Although there are no apparent hot spots in the MEN1 gene, there is a relative accumulation of mutations in some regions, such as codons 83-85, 209-211, and 516. Several different mutations in these regions have been reported in Caucasian families, and two of them were, despite the ethnic difference, identical to the mutation we have identified (359del4 and 1657insC). Bassett et al. (1988) reported that mutations in codons 83/84, 210/211, and 516 accounted for 6%, 11%, and 6%, respectively, of the mutations they identified. Five of the 14 families (36%) in our study also harbored mutations in one of these regions ( Table 1 ). The accumulation of mutations in such regions may reflect a structural susceptibility to mutation, rather than being of functional importance (Bassett et al. 1998) .
Identification of the responsible gene has enabled the genetic diagnosis of MEN 1. Before the isolation of the MEN1 gene, family members of patients needed to undergo an annual biochemical and radiological screening for early management of clinical manifestations (Vasen et al. 1989) . With genetic analysis, early diagnosis and better clinical management can be achieved for gene carriers. And for non-carriers, the annual screening of endocrine organs will become unnecessary. Also, for patients with single endocrine manifestations such as hyperparathyroidism, pituitary tumor, or pancreatic endocrine tumor, evaluation of the MEN1 gene in germline DNA will help to determine whether these lesions are initial manifestations of MEN 1 and whether future follow-up is necessary for other endocrine organs. However, it is to be noted that no mutations were found in some families with MEN 1 (Shimizu et al. 1997; Bassett et al. 1998) . Some of these families may have a large deletion in the MEN1 gene (Kishi et al. 1998) , but a family with the clinical features of MEN 1 but not linked to Agarwal et al. 1997; Shimizu et al. 1997 d Bassett et al. 1998 the MEN1 locus has also been reported (Stock et al. 1997) . Thus, absence of the MEN1 gene mutation, as determined by PCR and the following sequencing, cannot completely rule out the possibility that MEN 1 is present. In summary, we have identified a number of MEN1 gene mutations in families with MEN 1. The collection of many mutations, as well as functional analysis of wild-type and mutant menin protein, will facilitate our understanding of the molecular mechanism responsible for the tumorigenesis in MEN 1, and this, in turn, will enable better clinical management of patients with this syndrome.
